Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in plasmablast-high refractory multiple sclerosis
jRCTs031180346Completed
- Sponsor
- National Center of Neurology and Psychiatry
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab in multiple sclerosis (MS), sponsored by National Center of Neurology and Psychiatry. Primary endpoints: Adverse events after initiation of tocilizumab and Relapse rate compared to pretreatment period. Started Dec 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCTs031180346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180346.